Among the formerly undruggable targets gaining translational momentum, SMARCA2 has intrigued researchers for its potential to treat challenging solid tumors. On the latest BioCentury This Week podcast, BioCentury's editors zero in on preclinical research supporting different degraders of SMARCA2 at this year’s American Association for Cancer Research (AACR) annual meeting.
They also discuss takeaways from Editor in Chief Simone Fishburn’s conversation with David Baker, the Nobel-prizewinning pioneer in protein design, and Steve Usdin reports that pharmaceutical industry executives are in a state of alarm over President Trump’s push to include a “most favored nation” policy for Medicaid drug purchases in budget reconciliation legislation. Usdin also discusses why industry executives are confident of a fix for the Inflation Reduction Act’s “pill penalty” and FDA Commissioner Marty Makary’s decision to reject proposals to reorganize the agency. This episode was sponsored by Jeito Capital.

View full story: https://www.biocentury.com/article/655851

#biotech #biopharma #pharma #LifeScience #RandD #DrugDevelopment #AACR #SMARCA2

00:01 - Sponsor Message: Jeito Capital
03:01 - AACR Spotlight
11:21 - David Baker Protein Design
19:12 - Trump's Drug Pricing Plan

To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.

Reach us by sending a text

Ep. 294 - AACR Spotlight on SMARCA2 degraders. Plus: David Baker, Drug Pricing

BioCentury This Week